ISSN: 2147-2092
The Predictive Value of Inflammatory Markers in the First Year of Diagnosis in Ulcerative Colitis
PDF
Cite
Share
Request
Original Investigation
VOLUME: 31 ISSUE: 2
P: 163-168
July 2020

The Predictive Value of Inflammatory Markers in the First Year of Diagnosis in Ulcerative Colitis

GMJ 2020;31(2):163-168
DOI: 10.12996/gmj.2020.42
Rezzan Eren Sadioğlu 1
Tarkan Karakan 2
1. Gazi University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey
2. Gazi University Faculty of Medicine, Department of Gastroenterology, Ankara, Turkey
No information available.
No information available
Received Date: 18.02.2019
Accepted Date: 31.01.2020
PDF
Cite
Share
Request

ABSTRACT

Objective:

The aim of this study was to determine if the changes in inflammatory markers which were observed during the routine follow-up of patients with ulcerative colitis could predict the disease progression.

Methods:

Levels of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hemoglobin (Hb), white blood cell count (WBC), neutrophil-lymphocyte ratio (NLR), mean platelet volume (MPV) and albumin (alb), which were observed at the time of diagnosis as well as in the 3rd, 6th, 9th and 12th months, were recorded retrospectively. The area under the curve (AUC) of the variation of these values with respect to time was calculated.

Results:

118 patients were subjects of this study, with a mean follow-up time of 3.4 years. The calculated AUCs for CRP, ESR, WBC, and NLO were significantly higher (p < 0.001, p < 0.01, p < 0.01, p < 0.01); whereas the ones for Hb, alb, and MPV were significantly lower (p < 0.01, p < 0.001, p < 0.05) in patients who used an immunomodulator compared to those who did not. The calculated AUCs for CRP and ESR were significantly higher (p < 0.001, p < 0.05); whereas the AUCs for Hb, alb, and MPV were significantly lower (p < 0.01, p < 0.05, p < 0.01) in patients who used an anti-tumor necrosing factor-alpha inhibitor (anti-TNF) compared to those who did not. Additionally, in patients who used anti-TNF, the AUCs for CRP were significantly higher (p < 0.05), than in patients who only used immunomodulators.

Conclusion:

The levels of inflammatory markers in the early course of the disease are helpful for predicting the disease progression and prognosis. We assume that, the higher the CRP, the worse the prognosis.